These changes warrant medical evaluation to distinguish between disease progression, medication storage issues, or other factors affecting treatment response
Usually, the tumor has a benign, locally aggressive behavior, with recurrence of 10% to 15%, being eventually malignant in 6.97%, and acquiring metastatic capacity due to the proliferation of neuroblastic cells, with metastasis described in regional lymph nodes, liver, pleura, bone marrow, and pelvis
Common week one experiences include mild appetite reduction that comes and goes, slight changes in how food tastes or appeals, occasional mild nausea, particularly after larger meals, and a subtle sense of fullness that arrives earlier during meals than usual
In the UK, the MHRA has approved semaglutide (Wegovy) and liraglutide (Saxenda) specifically for weight management in adults with obesity or overweight with weight-related comorbidities (as per NICE TA875 and TA664)